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Clinical Influenza Testing Practices in Hospitalized
Children at United States Medical Centers, 2015-2018
Mark W. Tenforde,1 Angela P. Campbell,1 Marian G. Michaels,2 Christopher J. Harrison,3 Eileen J. Klein,4 Janet A. Englund,4 Rangaraj Selvarangan,3,
Natasha B. Halasa,5 Laura S. Stewart,5 Geoffrey A. Weinberg,6, John V. Williams,2 Peter G. Szilagyi,7 Mary A. Staat,8 Julie A. Boom,9,10 Leila C. Sahni,9,10
Monica N. Singer,11 Parvin H. Azimi,11 Richard K. Zimmerman,12 Monica M. McNeal,13 H. Keipp Talbot,5 Arnold S. Monto,14 Emily T. Martin,14
Manjusha Gaglani,15, Fernanda P. Silveira,12 Donald B. Middleton,12 Jill M. Ferdinands,1 and Melissa A. Rolfes1

At nine US hospitals that enrolled children hospitalized with acute respiratory illness (ARI) during 2015-2016 through 2017-2018
influenza seasons, 50% of children with ARI received clinician-initiated testing for influenza and 35% of cases went undiagnosed due
to lack of clinician-initiated testing. Marked heterogeneity in testing practice was observed across sites.
Key words: antigen test; hospitalized; influenza; RT-PCR; testing.

Millions of influenza cases and thousands of influenza-associated
hospitalizations occur in children annually in the United States [1].
Clinical guidelines recommend influenza testing for all hospitalized children with an acute respiratory illness (ARI) while influenza is locally circulating [2]. Testing informs clinical decisions,
infection control, and understanding of locally circulating pathogens, and although influenza antiviral therapy should be initiated
immediately for suspected influenza in hospitalized patients to improve outcomes [3], it is rarely started without clinical testing [4].
The New Vaccine Surveillance Network (NVSN), a CDCfunded research network, performs protocol-driven influenza
research testing among hospitalized children meeting criteria for
ARI to determine influenza vaccine effectiveness annually [5, 6].
The network also collects details on independently performed
clinician-initiated influenza testing, allowing us to examine patterns of clinician-driven testing in patients hospitalized with
ARI. Within NVSN we: (1) evaluated the frequency of influenza
testing in children with ARI and how clinician-initiated testing
changed over three seasons; (2) assessed the heterogeneity of
testing practices by age and hospital site; and (3) evaluated the
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missed burden of hospitalized influenza cases due to lack of clinical testing. We hypothesized that a large proportion of hospitalized children with ARI do not receive influenza testing, and this
might result in a substantial burden of missed cases.
METHODS

NVSN enrolled children (<18 years) at eight academic medical
centers (9 individual hospitals). One hospital participated only
during the 2015-2016 influenza season and one only during
2016-2017 and 2017-2018 seasons. Children were eligible if
they resided within the surveillance area and visited the emergency department (ED) or were admitted to the hospital within
48 hours of enrollment and had ARI or a related syndrome (eg,
asthma exacerbation or pneumonia) in 2015-2016 [6]. During
2016-2017 and 2017-2018 seasons, the same eligibility criteria
were used, although an additional symptom criterion was added
(≥1 symptom of ARI without a known non-respiratory cause)
[5]. Children were not eligible if they were seen in the ED but
not admitted, symptom onset was >7 days before presentation,
or they received influenza antiviral therapy prior to admission.
Data including clinician-initiated influenza testing were
collected through medical records review of enrolled patients
by trained study staff. Staff collected data on influenza testing
performed either by rapid test or a molecular respiratory virus
panel. For rapid tests, information on assay type (antigen vs
molecular) was specified only for 2017-2018. We considered a
patient clinically tested for influenza if ≥1 assay was performed
throughout the hospitalization.
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RESULTS

During three seasons, 7356 children at 9 hospitals in 8 states
with ARI were included. Fifty percent (3688/7356) of included
children received clinician-initiated testing for influenza
(Table 1). Among patients who were clinically tested, 76%
(2802/3688) were tested using a molecular respiratory virus
panel. Restricted to those with ARI plus relevant ARI-related
ICD-10-CM codes, 56% (1552/2777) were clinically tested
for influenza. In comparison, among adults with ARI clinical
testing was performed in 64% overall and 78% enrolled with
ARI who also had an included ICD-10-CM diagnostic code
(Supplementary Appendix B).
We did not observe a temporal trend in clinician-initiated
testing across seasons (P = .20) for children with ARI; however,
we did find clinical testing significantly increased across the seasons (P = .019) for children with ARI plus an acute respiratory
6 • jpids 2022:11 (January) • Tenforde et al

Table 1. Clinician-Initiated Influenza Testing by Season and Age Group
for Patients Meeting Criteria for Acute Respiratory Illness (ARI) or with
Pneumonia and Influenza (P&I) or ARI International Classification of
Disease, 10th Edition (ICD-10-CM) Discharge Diagnoses
Population and Test Type

2015-2016
Season

2016-2017
Season

2017-2018
Season

0- to 4-year-olds
Acute respiratory illnessa

n = 2025

n = 1923

n = 1860

Any influenza testing, % (No.)

52% (1050)

48% (927)

53% (989)

Molecular respiratory panel, % (No.)

38% (772)

40% (760)

39% (726)

Singleplex/rapid molecular, % (No.)

—

—

6% (109)

16% (330)

14% (277)

16% (292)

Rapid antigen, % (No.)b
ICD-10-CM discharge diagnosis

n = 653

n = 639

n = 671

Any influenza testing, % (No.)

56% (364)

54% (347)

56% (378)

Molecular respiratory panel, % (No.)

39% (257)

42% (271)

39% (265)

Singleplex/rapid molecular, % (No.)

—

—

7% (46)

19% (125)

20% (129)

19% (128)

Rapid antigen, % (No.)b
5- to 17-year-olds
Acute respiratory illnessa

n = 525

n = 549

n = 474

Any influenza testing, % (No.)

38% (202)

49% (268)

53% (252)

Molecular respiratory panel, % (No.)

30% (158)

39% (215)

36% (171)

Singleplex/rapid molecular, % (No.)

—

—

4% (21)

13% (66)

17% (91)

20% (93)

Rapid antigen, % (No.)b
ICD-10-CM discharge diagnosis

n = 274

n = 278

n = 262

Any influenza testing, % (No.)

51% (139)

58% (161)

62% (163)

Molecular respiratory panel, % (No.)

40% (110)

44% (122)

39% (103)

Singleplex/rapid molecular, % (No.)

—

—

6% (16)

18% (50)

24% (68)

26% (68)

Rapid antigen, % (No.)b

No. = number tested.
Season for defined here as December 1 through April 30.
a
Numbers of individual test types may add up to greater than total number tested as some patients were
tested using more than one type of assay.
b
The New Vaccine Surveillance Network only specified if the rapid test was antigen-based or molecular during
the 2017-2018 season. Among patients with acute respiratory illness during the 2017-2018 season, 130/515
(25%) of rapid tests were molecular with the rest rapid antigen tests. For the 2015-2016 and 2016-2017 seasons, we classify all rapid tests in the table as antigen-based assays in the table.

infection-associated ICD-10-CM diagnosis, from 54% in 20152016 to 58% in 2017-2018 (Figure 1). Little change in testing was
observed in younger children (aged 0-4 years), including those
with ARI as well as those with ICD-10-CM diagnostic codes
for respiratory infections. Significant heterogeneity was observed in testing by hospital (all P < .001; Supplementary Table
2). Among children with ARI, hospital testing ranged by as
much as 27% (76/278) to 88% (188/214), during the 2016-2017
season. Among the 50% of children enrolled with ARI who received clinician-initiated testing, 8% (294/3688) had a positive
research influenza RT-PCR test result. Among enrolled children
who did not receive clinician-initiated testing, 4% (155/3668)
of research RT-PCR tests were positive. Thus, assuming perfect
specificity of the research RT-PCR, 35% (155/449) of the total
burden of influenza was missed due to the absence of clinicianinitiated testing.
DISCUSSION

Results from this study conducted over three recent influenza seasons in the United States provide insights into
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We calculated the number and percentage of children with
ARI who received clinician-initiated testing by age (0-4 and
5-17 years) between December and April. Because research
definitions for ARI may lack specificity and because of minor
differences in research ARI criteria used between seasons, we
also assessed clinician-initiated testing restricted to participants
with ARI who also had one or more International Classification
of Disease, Clinical Modification, 10th Edition (ICD-10-CM)
codes for acute upper respiratory infection (J00-J06), influenza
and pneumonia (J09-J18), or other acute lower respiratory infections (J20, J22) (Supplementary Appendix A, Supplementary
Table 1) [7]. We excluded bronchiolitis (J21) as guidelines
recommend laboratory testing not be routinely obtained [8].
Trends in the proportion tested over three influenza seasons
were assessed using a linear mixed model treating site as a
random effect and weighted for the number of enrolled participants. We further evaluated testing by hospital site, assessing
heterogeneity using chi-square tests.
To provide insight into the missed burden of hospitalized
influenza illness in children with ARI, we determined the proportion who tested positive for influenza by research RT-PCR
testing by clinician-initiated testing status. Assuming research
RT-PCR testing had near-perfect specificity, we assessed the
number and proportion of children with influenza diagnosed
through research testing who were not diagnosed by providers
due to lack of clinician-initiated testing. Local clinicians were
not aware of research testing results. To compare testing practices with children, we also evaluated clinician-initiated influenza testing practices among adults with ARI enrolled in a
separate hospital-based adult vaccine effectiveness network
(methods and results in Supplementary Appendix B). P-values
<.05 were considered significant. Analyses were performed
using SAS Version 9.4 (Cary, NC, USA) and R Version 3.6.1
(Vienna, Austria).

clinician-initiated influenza testing among hospitalized
children with ARI. The proportion tested for influenza was relatively low at 50% but differed markedly by hospital. Restricted to
children with ARI plus a respiratory illness-related ICD-10-CM
code, performance of clinical testing increased to 56%. A lack
of clinician-initiated testing resulted in a failure to identify
about one-third of children with influenza detected by research
testing. These findings suggest there are some opportunities to
improve decision pathways for influenza testing.
For children hospitalized with ARI, decisions about whether
to test for influenza or other respiratory viruses may involve a
variety of considerations. Indiscriminate testing for circulating
respiratory viruses can lead to added laboratory costs and low diagnostic yield; even among children clinically tested for influenza
at NVSN sites, research RT-PCR testing was positive in <10%.
However, the use of guideline-recommended testing of hospitalized children with ARI also has a variety of direct and indirect
benefits including promoting use of influenza antiviral therapy,
avoiding antibiotic overuse, hospital cohorting for infection prevention, and understanding of the epidemiology of locally circulating respiratory pathogens. The marked heterogeneity observed
in testing practices between hospitals suggests under-testing in
some hospitals based on local practices. Future analyses should
evaluate factors associated with influenza testing practices in hospitalized children and optimizing decision pathways.
In addition to supporting clinical decision making, findings from this study support public health efforts to assess the
true burden of severe illness due to influenza [9]. Surveillance
systems that rely on clinician-testing alone will systematically
underestimate the burden of respiratory infections. Accurate

estimates of the burden of respiratory infections—both diagnosed and undiagnosed—have broad implications. These
include promoting public awareness of the impact of infections and the importance of receiving vaccination, promoting
non-pharmaceutical interventions, and guiding health policy
decisions.
One strength of our analysis is that we examined testing
practices among hospitalized patients using 2 criteria. This included protocol-defined ARI criteria which are meant to be sensitive but lack specificity. We also evaluated clinician-initiated
influenza testing among patients with respiratory illness-related
ICD-10-CM codes which are more specific and capture illnesses
assigned to the patient during admission. Although clinical
testing was higher in children with relevant ICD-10-CM diagnoses, among those with included ICD-10-CM codes only 56%
received clinician-initiated testing over three influenza seasons.
Our study has several limitations. First, the pre-specified
ARI symptoms were intentionally broad for research purposes; however, case definitions are less specific for influenza
and could lead to an underestimate of the proportion clinically
tested. Secondly, we collected data during only three influenza
seasons and clinical testing practices by be influenced by additional time-varying factors such as circulation of SARS-CoV-2.
Finally, we captured data from hospitals that are geographically
diverse but may not be generalizable.
CONCLUSION

Clinician-initiated influenza testing among children hospitalized with ARIs occurred in one-half of patients and was similar
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Figure 1. Percentage of children with acute respiratory illness (ARI) receiving influenza clinician-initiated testing by influenza season and hospital in
children* enrolled in the New Vaccine Surveillance Network—the United States, 2015-2018. *Sites with <50 patients enrolled with ARI during a given season
are not shown in the figure. Lines are used to connect individual hospital sites values by season. Some hospitals did not participate during all seasons or may
have had <50 patients included with ARI during the season.

across three seasons. Opportunities exist for reinforcing influenza testing recommendations for patients hospitalized with
ARI.
Supplementary Data
Supplementary materials are available at the Journal of the Pediatric
Infectious Diseases Society online.
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